Objectives: Peroxisome proliferator activated receptor  (PPAR) acts as a fatty acid sensor to orchestrate the transcription of genes coding for rate-limiting enzymes required for lipid oxidation in hepatocytes. Mice only lacking Ppar in hepatocytes spontaneously develop steatosis without obesity in aging. Altough steatosis is a benign condition it can develop into non alcoholic steatohepatitis (NASH), which may progress to irreversible damage, such as fibrosis and hepatocarcinoma. While NASH appears as a major public health concern worldwide, it remains an unmet medical need. Several drugs are being tested in clinical trials, including pharmacological agonists for the different PPAR isotypes. In current study, we investigated the role of hepatocyte PPAR in a preclinical model of steatosis.
Introduction
Non alcoholic fatty liver disease (NAFLD) has become a major public health concern worldwide [1]. NAFLD ranges from benign steatosis to non alcoholic steatohepatitis (NASH), which may progress to irreversible damage, such as fibrosis or hepatocarcinoma. The hallmark of NAFLD is an elevated level of neutral lipids, which accumulate as lipid droplets in hepatocytes [2] . Although the aetiology of the disease is not fully understood, it is strongly associated with obesity and type 2 diabetes (T2D). In human NAFLD, the fatty acids that accumulate in hepatocytes originate mostly from adipose tissue lipolysis and hepatic de novo lipogenesis [3] . In T2D, adipose tissue insulin resistance promotes lipolysis, whereas hyperglycaemia combined with hyperinsulinemia sustains hepatic de novo lipogenesis [4] .
Given the burden of the NAFLD epidemic, identifying molecular players that can be targeted is a rather important issue [5, 6] . Moreover, finding drugs that may be used to treat NASH and its progression to irreversible liver disease is a so far unmet medical need to be solved [7, 8] . Among drugs currently being tested in clinical trials are a number of molecules that activate the peroxisome proliferator activated receptors (PPARs) [7, 9] . Three PPAR isotypes are known (, β/, and γ), and they are members of the nuclear receptor family, which act as fatty acid sensors that orchestrate transcription in response to a variety of endogenous ligands [9] , such as fatty acids [10] , fatty acid derivatives [11] and phospholipids [12] . Once activated by the binding of these lipids, PPARs may either induce or repress the expression of their specific target genes. PPARs are influential regulators of genes involved in metabolism in different tissues [13] . Therefore, several pharmacological agonists have been developed, tested on preclinical models of NAFLD [14, 15] , and are currently being either used or tested in clinical trials for the treatment of metabolic diseases [9] , and especially NAFLD [15] .
PPAR is the most abundant PPAR isotype in the healthy liver [16] and in hepatocytes, PPAR regulates the expression of thousands of genes and contributes to the remarkable metabolic flexibility of the liver [17] [18] [19] [20] . PPAR is particularly active during suckling [21] [22] [23] and fasting [18, 19, [24] [25] [26] [27] , two conditions in which fatty acids are a preferred source of energy for the organism. PPAR is also expressed in many other tissues, including skeletal muscle [28] , adipose tissues [29] [30] [31] [32] , intestine [33] , heart [34] , and kidney [35] . Germline deletion of Ppar renders mice susceptible for many metabolic defects including obesity [36] , steatosis [36, 37] , and NASH [38, 39] , but not diabetes [40, 41] . We have showed recently that a hepatocyte-specific deletion of Ppar induces spontaneous steatosis in aging mice and blunts fasting-induced ketogenesis [18, 19] . Moreover PPAR is required for the expression of fibroblast growth factor 21 (FGF21) [42, 43] , a liver-derived hormone with many endocrine [44] and hepatoprotective effects [45, 46] .
In the present study, we evaluated the importance of hepatocyte PPAR in steatosis associated with diet-induced obesity. We provide evidence that in mice fed with a high fat diet (HFD), Ppar deletion in hepatocytes is sufficient to promote NAFLD. In addition, analysis of the hepatic transcriptome, lipidome, and metabolome, demonstrated that extrahepatic PPAR activity significantly contributes to metabolic homeostasis in response to HFD consumption.


Material and Methods
Mice
In vivo studies were conducted under the EU guidelines for the use and care of laboratory animals and they were approved by an independent ethics committee. Ppar-deficient C57BL/6J mice (Ppar -/-) were bred at INRA's transgenic rodent facility.
Age-matched C57BL/6J (provided by Charles River) were acclimated to the local animal facility conditions prior to the experiment. Mouse housing was controlled for temperature and light (12-h light/12-h dark). All mice were placed in a ventilated cabinet at the specific temperature of 30°C (thermoneutrality) throughout the experiment. All animals used in these experiments were male mice.
Oral glucose tolerance test
Mice were fasted for 6 h and received an oral (2g/kg body weight) glucose load. Blood glucose was measured at the tail vein using an AccuCheck Performa glucometer (Roche Diagnostics) at -15, 0, 15, 30, 45, 60, 90, and 120 minutes.
Blood and tissue samples
Prior to sacrifice, blood was collected in EDTA-coated tubes (BD Microtainer, K2E tubes) from the submandibular vein. All mice were killed in a fed state. Plasma was collected by centrifugation (1500xg, 10min, 4°C) and stored at -80°C. Following killing by cervical dislocation, the organs were removed, weighted, dissected and used for histological analysis or snap-frozen in liquid nitrogen and stored at -80°C. 
Gene expression
Histology
Formalin-fixed, paraffin-embedded liver tissue was sliced into 3-μm sections and stained with haematoxylin and eosin for histopathological analysis. The staining was visualized with a Leica microscope DM4000 B equipped with a Leica DFC450 C camera. The histological features were grouped into two categories: steatosis and inflammation. The steatosis score was evaluated according to Contos et al. [47] . Liver slices were assigned a steatosis score depending on the percentage of liver cells containing fat: Grade 0, no hepatocytes involved in any section; grade 1, 1% to 25% of hepatocytes involved; grade 2, 26% to 50% of hepatocytes involved; grade 3, 51% to 75% of hepatocytes involved and grade 4, 76% to 100% of hepatocytes involved. For the inflammation score, inflammatory foci were counted into 10 distinct areas at 200x for each liver slice. Values represent the mean of 10 fields/liver slice.
Biochemical analysis
Aspartate transaminase (AST), alanine transaminase (ALT), total cholesterol, LDL and HDL cholesterols were determined from plasma samples using a COBASMIRA+ biochemical analyser (Anexplo facility).
Analysis of liver neutral lipids
Tissue samples were homogenized in methanol/5 mM EGTA (2:1, v/v), and lipids (corresponding to an equivalent of 2 mg tissue) extracted according to the Bligh-Dyer method [48] , with chloroform/methanol/water (2.5:2.5:2 v/v/v), in the presence of the following internal standards: glyceryl trinonadecanoate, stigmasterol, and cholesteryl heptadecanoate (Sigma).
Triglycerides, free cholesterol, and cholesterol esters were analysed by gas-liquid chromatography on a Focus Thermo Electron system equipped with a Zebron-1 Phenomenex fused-silica capillary column (5 m, 0.25mm i.d., 0.25 mm film thickness). The oven temperature was programmed to increase from 200 to 350°C at 5°C/min, and the carrier gas was hydrogen (0.5 bar). The injector and detector temperatures were 315°C and 345°C, respectively.
Liver fatty acid analysis
To measure all hepatic fatty acid methyl ester (FAME) molecular species, lipids that corresponded to an equivalent of 1 mg of liver were extracted in the presence of the internal standard, glyceryl triheptadecanoate (2 μg) [49] . The lipid extract was transmethylated with 1 ml BF3 in methanol (14% solution; Sigma) and 1 ml heptane for 60 min at 80°C, and evaporated to dryness. The FAMEs were extracted with heptane/water (2:1). The organic phase was evaporated to dryness and dissolved in 50 μl ethyl acetate. A sample (1 μl) of total FAME was analysed by gas-liquid chromatography (Clarus 600 Perkin Elmer system, with
Famewax RESTEK fused silica capillary columns, 30-m×0.32-mm i.d., 0.25-μm film thickness).
The oven temperature was programmed to increase from 110°C to 220°C at a rate of 2°C/min, and the carrier gas was hydrogen (7.25 psi). The injector and detector temperatures were 225°C and 245°C, respectively.
Liver phospholipid and sphingolipid analysis 2.10.1 Chemicals and reagents
The liquid chromatography solvent, acetonitrile, was HPLC-grade and purchased from Acros Organics. Ammonium formate (>99%) was supplied by Sigma Aldrich. Synthetic lipid standards (Cer d18:1/18:0, Cer d18:1/15:0, PE 12:0/12:0, PE 16:0/16:0, PC 13:0/13:0, PC 16:0/16:0, SM d18:1/18:0, SM d18:1/12:0) were purchased from Avanti Polar Lipids.
Lipid extraction
Lipids were extracted from the liver (1 mg) as described by Bligh 
Results
Hepatic and total Pparα deficiencies dissociate HFD-induced obesity and fatty liver from glucose intolerance
Male mice from different genotypes, namely wild-type (WT), germline Ppar-null (Ppar -/-) and hepatocyte-specific Ppar-null (Ppar hep-/-), were fed a low-fat diet (10% fat, CTRL) or a HFD (60% fat) at 8 weeks of age for 12 weeks at thermoneutrality (30°C). At the beginning of the experiment, the Ppar -/mice were already significantly heavier than the WT and Ppar hep-/mice ( Figure 1A,B ). All mice, independently of the genotype became overweight and gained approximately 15g in response to HFD consumption ( Figure 1A ). Moreover, unlike
WT and Ppar hep-/mice, Ppar -/mice on CTRL diet also gained significant body weight.
Therefore, Ppar -/mice became more overweight than Ppar hep-/and WT mice at thermoneutrality. In CTRL mice, oral glucose tolerance (OGTT) tested after 10 weeks of HFD feeding was similar regardless of the genotype ( Figure 1C and D) . In the HFD-fed groups, WT mice became glucose intolerant whereas Ppar hep-/and Ppar -/mice were protected against this intolerance ( Figure 1C and D) . These results are consistent with fasted glucose levels that increased in response to HFD only in WT mice, but not in Ppar hep-/or Ppar -/mice ( Figure   1E ). Therefore, HFD feeding leads to fasting hyperglycaemia and glucose intolerance in WT mice, but not in Ppar hep-/and Ppar -/mice.
Different biochemical analyses were performed in plasma from fed animals ( Figure 1F ).
Cholesterol, LDL-cholesterol, and HDL-cholesterol tended to increase in response to HFD diet in all three genotypes. However, we found that levels of the 3 lipid parameters were higher in the plasma of Ppar hep-/mice than plasma from Ppar -/mice. Triglycerides were elevated in 
Hepatic and total Pparα deficiencies promote liver steatosis, inflammation, and injury in HFD-induced obesity
Next, we performed histological analysis in order to investigate whether the lack of Ppar either globally or liver specific was associated with changes in liver integrity (Figure 2A) .
First, we observed that Ppar hep-/and Ppar -/mice developed steatosis upon CTRL diet feeding. In HFD, steatosis in Ppar hep-/and Ppar -/mice was much more severe than for WT mice, which is in agreement with their respective liver weight ( Figure 2B ). To better characterize liver injury, steatosis and inflammation scoring were performed ( Figure 2C and E). The steatosis score revealed that Ppar hep-/and Ppar -/mice fed a HFD exhibited increasing lipid droplet deposition in the liver compared to WT mice ( Figure 2C ), which is confirmed by measurement of triglyceride liver content ( Figure 2D ). Inflammation scoring revealed that HFD did not significantly increase hepatic inflammation in WT mice ( Figure 2E ), contrarily to both Ppar -/and Ppar hep-/mice. In agreement with increased inflammation, plasma markers of liver injury (ALT and AST) were significantly increased in HFD fed Ppar -/and Ppar hep-/mice ( Figure 2F ).
Gene expression profile in WT, Pparα hep-/-, and Pparα -/mice in response to HFD-induced obesity
Next, we evaluated the hepatic transcriptome expression pattern in response to HFD using microarrays. Overall, we identified a total of 8115 differentially expressed probes (corresponding to 7173 genes) sensitive to HFD feeding in at least one of the three genotypes (based on adjusted p-value; FDR<5%). Hierarchical clustering of probes highlighted 12
clusters showing specific gene expression profiles according to the experimental conditions ( Figure 3A ). Four of them (clusters 1, 2, 3 and 4) showed a typical transcriptomic pattern in Ppar -/mice compared to Ppar hep-/and WT mice regardless of diet. Interestingly, the liver transcriptome was also influenced by HFD in a genotype-specific manner ( Figure 3A) . The microarray analysis was validated by qPCR measurements of different genes ( Figure 3B ). The expression of Vnn1, encoding a liver-enriched oxidative stress sensor involved in the regulation of multiple metabolic pathways, was identified as an HFD-responsive gene specific to the WT mice. The expression of Fmo3, which produced trimethylamine N-oxide (TMAO) was identified as an HFD-induced gene specifically in Ppar -/mice. The expression of collagen Col1a1 is largely increased by HFD in the absence of hepatocyte-specific or wholebody Pparand not in WT mice. Lastly, Ppar-γ2 was identified as an HFD-responsive gene common to the three mouse genotypes. Significant overlaps occur between differentially expressed genes (DEGs) in the three genotypes ( Figure 3C ). Interestingly, only 387 DEGs were sensitive to HFD in all 3 genotypes at p<0.05, 232 at p<0.03 and 95 at p<0.01, mostly involved in metabolic regulations ( Figure 3C and Supplementary Figure 1 ). This represents between 3 and 5% of all HFD-sensitive genes for which HFD regulation is strictly independent from hepatocyte or whole-body PPAR, therefore illustrating the critical role of the nuclear receptor in the liver response to a hyperlipidic diet.
PPAR-dependent changes in hepatic gene expression profiles in response to HFD induced obesity
A large group of DEGs include 922 genes significantly up-regulated and 857 significantly down-regulated by HFD feeding only in WT mice ( Figure 4A) . Examples of these genes include well-established PPAR targets, such as Cyp4a14, Acot3, Acot2, and Fitm1
( Figure 4B ), and eight categories of genes involved in metabolism ( Figure 4C ) with upregulated expression in response to a HFD only in WT mice. However, we also identified four KEGG categories down-regulated in response to HFD specifically in WT mice. These categories relate to RNA transport, ribosome activity and protein processing ( Figure 4D ). The venn diagram ( Figure 3C ) also reveals a large group of DEGs modulated only in Ppar hep-/mice fed a HFD compared to CTRL diet which encompassed 630 and 865 significantly up or down-regulated genes, respectively ( Supplementary Figure 2) . Figure 3C also defines a third large group of DEGs including 1143 and 1257 genes significantly up-regulated and downregulated, respectively, by HFD feeding only in Ppar -/mice ( Supplementary Figure 3) . This suggests that the hepato-specific and whole-body deletions of Ppar have distinct and specific consequences in the hepatic response to HFD-induced obesity.
3.5.
Hepatocyte PPAR prevents liver inflammatory gene expression in response to HFD
Next, we questioned whether deletion of Ppar in hepatocytes only or in the wholebody induces some similar responses in HFD-induced obesity. We identified a group of DEGs including 337 and 349 genes significantly up-regulated or down-regulated, respectively, by HFD feeding in both Ppar -/and Ppar hep-/mice ( Figure 5A ). Gene category analysis did not reveal any functions related to the 349 down-regulated genes by HFD feeding in Ppar -/or Ppar hep-/mice. However, gene category analysis highlighted the functions related to the 337 genes significantly up-regulated by HFD feeding in both Ppar -/and Ppar hep-/mice ( Figure   5B ), suggesting that these genes are negatively regulated by PPAR Most of these categories relate to the inflammatory process, including the NF-kappa B, TNF, and TLR signalling pathways. We selected the genes directly related to these pathways using the KEGG database and the gene database network ( Supplementary Figure 4) and confirmed a marked upregulation of genes belonging to NF-kappa B, TNF, and TLR in the hepatocyte-specific or whole-body absence of Ppar ( Figure 5C ), in accordance with inflammatory markers measured ( Figure 2E ).
Metabolic and lipidomic profiling of PPAR-dependent regulation of hepatic homeostasis in response to HFD
We performed unbiased hepatic metabolomic profiling of aqueous metabolites using proton nuclear magnetic resonance ( 1 H-NMR). We used a projection to latent structures for discriminant analysis (PLS-DA) to investigate whether there was a separation between experimental groups of observations. A valid and robust PLS-DA model was obtained that discriminated HFD-fed Ppar -/mice from all other groups (Supplementary Figure 5) , further supporting the role of non-hepatocytic PPAR activity in hepatic homeostasis in response to HFD.
We also performed a targeted analysis of 75 lipid species including neutral lipids (cholesterol, cholesterol esters, and triglycerides), phospholipids, and sphingolipids. The relative abundance of each species in the livers of WT, Ppar -/-, and Ppar hep-/mice fed with either of the two diets (CTRL and HFD) was evaluated to determine the contribution of hepatocyte and whole body PPAR activity to hepatic lipid homeostasis. The results are presented as a heatmap with hierarchical clustering (Figure 6A) , in which we observed that the samples first clustered according to the diet, demonstrating that HFD-feeding was the main discriminating factor for hepatic lipid content. We identified four main clusters of lipids with distinct profiles relative to the different experimental conditions. Lipids in cluster 1, such as the ceramides d18:1/C18:1, d18:1/C18:0, and d18:1/C26:0 ( Figure 6B ), exhibit increased relative abundance in HFD-fed Ppar -/mice, suggesting that extra-hepatocytic PPAR contributes predominantly to lipid remodelling during HFD-feeding. Cluster 1 also contains linoleic acid (C18:2n-6), which exhibits increased abundance in HFD-fed Ppar -/mice, but also in HFD-fed Ppar hep-/mice. Lipids in cluster 2, such as the phospholipids PC36:3, PC28:6, PE38:4, and triglyceride TG C57 ( Figure 6C ), are less abundant in HFD Ppar -/mice. Lipids in cluster 3, such as the palmitoleic acid (C16:1n-7) and PE32:1 (Figure 6D ), are less abundant in HFD mice from the three genotypes. Lipids in cluster 4 ( Figure 6E ), such as the polyunsaturated fatty acids C20:4n-6 and C22:5n-3 are more abundant in WT mice from the CTRL diet group and reduced in the livers of mice fed a HFD.
Overall, this lipidomic profiling highlights that the hepatic lipidome depends both on the genotype and diet. Therefore, both hepatic Ppar and whole body Ppar deletions result in a specific lipidomic response to HFD feeding. However, whole body Ppar deficiency has a stronger influence on the effect of HFD-induced obesity on liver metabolic homeostasis.
Discussion
NAFLD is the hepatic manifestation of the obesity epidemic and represents a major public health issue worldwide [50] . NAFLD ranges from benign steatosis to NASH and may promote liver fibrosis and cancer. Therefore, there is a great interest in drugs that could be used to cure NAFLD or reverse NASH before it promotes irreversible damage [7] . PPAR, and other PPAR isotypes represent targets currently being tested in clinical trials [9, 51, 52] . PPAR is a ligandactivated nuclear receptor that plays a key role in the regulation of metabolic homeostasis by modulating the expression of rate-limiting enzymes involved in fatty acid degradation [17] [18] [19] .
Preclinical studies in Ppar null mice have shown that PPAR protects from steatosis [18, 53] and NASH. Moreover, several clinical lines of evidence indicate that PPAR is also influential in human NASH [54] .
Most studies performed in vivo in Ppar null mice have suggested that the mechanisms by which PPAR protects from steatosis and NASH involve its ability to transactivate genes required for fatty acid catabolism and to repress a number of inflammatory genes [38, 39] .
Because PPAR is expressed in many cell types and tissues with high fatty acid oxidation activity [28] [29] [30] 33] , it is interesting to define in vivo the specific contribution of hepatocytic PPAR in preventing NAFLD.
When fed a regular diet, Ppar -/mice are steatotic and overweight as previously reported [25, 37] . When fed a HFD, they become even more steatotic and develop further liver inflammation and NASH injury [38, 39] . Importantly, although Ppar-null mice develop steatosis, they do not exhibit reduced glucose tolerance compared to WT mice [41] . The data we obtained in Ppar hep-/mice fed a HFD indicate that the deletion of Ppar in hepatocytes is sufficient to promote steatosis and marked signs of fibrosis and inflammation. As in Pparα-null mice, despite enhanced steatosis compared to HFD-fed WT mice, HFD-fed Ppar hep-/mice do not exhibit enhanced glucose intolerance. Therefore, hepatocyte-specific Ppar deletion promotes steatosis and liver inflammation. Interestingly, it also dissociates steatosis from glucose intolerance as observed in Ppar -/mice [40, 41] .
The mechanisms involved in the susceptibility to steatosis and protection from glucose intolerance likely involve the well-established role of PPARα in the control of fatty acid transport and degradation [17] . The mechanisms by which hepatocyte Ppar deficiency promotes NASH likely involve lipotoxic fat accumulation, including linoleic acid (C18:2n-6), which was recently identified as promoting NAFLD etiology in vivo [55] . Moreover, we extend previous observations and confirm the role of hepatocyte PPARα in repressing the expression of inflammatory genes, such as those involved in the NF-kappa B pathway [56, 57] .
This study not only shows a specific effect of hepatocyte PPARα activity, but also identifies several roles of non-hepatocytic PPARα. First, we confirmed our previous observations that, unlike Ppar hep-/mice, Ppar -/mice gain weight when fed a regular diet [18] . Moreover, because the current observations were made at thermoneutrality, this weight gain is not likely due to defective PPAR expression and activity in the brown adipose tissue. In addition, by combining different large or medium scale analyses of the liver transcriptome and metabolome, we showed that the response to HFD was different in Ppar -/mice compared to Ppar hep-/mice, showing that extra-hepatocyte PPAR mediates at least a part of the adaptive response to HFD. These data are in agreement with a recent study providing evidence that extrahepatic PPAR such as in skeletal muscle and heart, may contribute to whole-body fatty acid homeostasis [58] .
Taken together, our data demonstrate that hepatocyte-specific deletion of Ppar promotes steatosis and NASH in HFD-induced obesity and provide further pre-clinical evidence that hepatocyte PPAR is a relevant direct target in NAFLD. Our data also suggest that extrahepatic PPAR plays a major homeostatic role in the control of the metabolic response to HFD. Further research is required to investigate in which organ, other than liver, PPAR regulates lipid metabolism in health and disease. 
Figure legends
